ConductScience.org, home

Trial · NCT04282629

Registered outcomes22

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
Primaryvolume of delayed cerebral ischemia lesions1 monthvolume of DCI lesions measured on CT scan and validated by Magnetic Resonance Imaging (MRI) imaging at 1 month
SecondaryRadiological parameters on CT at 1 month1 monthpercentage of patients with DCI lesions
SecondaryEvolution in intensive care: Neurological complications 11 monthnumber of episodes of PtiO2 below the ischemic threshold in intensive care: PtiO2 \<20 mmHg (moderate hypoxia) and \<15 mm Hg (severe hypoxia) for at least 15 minutes
SecondaryEvolution in intensive care: Neurological complications 21 monthtotal duration of episodes of PtiO2 \<20 mm Hg (moderate hypoxia) and \<15 mm Hg (severe hypoxia)
SecondaryEvolution in intensive care: Neurological complications 31 monthnumber of recourse to an endovascular treatment
SecondaryEvolution in intensive care: Neurological complications 41 monthintracranial hypertension in intensive care: ICP\> 20 mmHg for at least 15 minutes.
SecondaryNumber and type of non-neurological complications1 monthnon-neurological complications
SecondaryNumber of days in intensive care1 monthNumber of days in intensive care
SecondaryNumber of days with mechanical ventilation1 monthNumber of days with mechanical ventilation
Secondaryneurological prognosis at 1 month: Rankin score1 monthevaluated by the modified Rankin score (good prognosis: mRS 0, 1 and 2 / poor prognosis: mRS 3, 4 and 5)
Secondaryneurological prognosis at 1 month: Glasgow Outcome scale1 monthevaluated by the Glasgow Outcome Scale (GOS) (good prognosis: GOS 4 and 5 / poor prognosis: GOS 1, 2 and 3).
Secondaryneurological prognosis at 3 month: Rankin score3 monthevaluated by the modified Rankin score (good prognosis: mRS 0, 1 and 2 / poor prognosis: mRS 3, 4 and 5)
Secondaryneurological prognosis at 3 month: Glasgow Outcome scale3 monthevaluated by the the Glasgow Outcome Scale (good prognosis: GOS 4 and 5 / poor prognosis: GOS 1, 2 and 3)
Secondaryneurological prognosis at 6 month: Rankin score6 monthevaluated by the modified Rankin score (good prognosis: mRS 0, 1 and 2 / poor prognosis: mRS 3, 4 and 5)
Secondaryneurological prognosis at 6 month: Glasgow Outcome scale6 monthevaluated by the the Glasgow Outcome Scale (good prognosis: GOS 4 and 5 / poor prognosis: GOS 1, 2 and 3)
Secondaryneurological prognosis at 1 year: Rankin score1 yearevaluated by the modified Rankin score (good prognosis: mRS 0, 1 and 2 / poor prognosis: mRS 3, 4 and 5)
Secondaryneurological prognosis at 1 year: Glasgow Outcome scale1 yearevaluated by the Glasgow Outcome Scale (good prognosis: GOS 4 and 5 / poor prognosis: GOS 1, 2 and 3)
SecondaryMortality at 1 month1 monthMortality at 1 month
SecondaryMortality at 3 month3 monthMortality at 3 month
SecondaryMortality at 6 month6 monthMortality at 6 month

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04282629/registered